Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management

To further characterize the safety of tepotinib in patients with MET exon 14 skipping non-small cell lung cancer, we analyzed adverse events of clinical interest in the phase II VISION trial (N = 255). The most frequent adverse events were largely mild/moderate and manageable with supportive measure...

Descripción completa

Detalles Bibliográficos
Autores principales: Veillon, Remi, Sakai, Hiroshi, Le, Xiuning, Felip, Enriqueta, Cortot, Alexis B., Smit, Egbert F., Park, Keunchil, Griesinger, Frank, Britschgi, Christian, Wu, Yi-Long, Melosky, Barbara, Baijal, Shobhit, de Castro, Gilberto, Sedova, Michaela, Berghoff, Karin, Otto, Gordon, Paik, Paul K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068910/
https://www.ncbi.nlm.nih.gov/pubmed/35466070
http://dx.doi.org/10.1016/j.cllc.2022.03.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068910/
https://www.ncbi.nlm.nih.gov/pubmed/35466070
http://dx.doi.org/10.1016/j.cllc.2022.03.002

Ejemplares similares